• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Study Finds Particulate Matter Exposure Associated With Incident CKD


A study conducted in China found that long-term exposure to ambient particulate matter increased the risk of chronic kidney disease (CKD).

High levels of ambient particulate matter (PM2.5) significantly increased the risk of chronic kidney disease (CKD), according to new study findings published in American Journal of Kidney Diseases. The aim of the study was to estimate the risk of incident CKD associated with long-term exposure to ambient PM2.5 in mainland China.

The longitudinal study took place in Hunan, China, between 2005 and 2018. All participants (N = 72,425) underwent an annual physical examination at the Health Management Center in the Third Xiangya Hospital of Central South University.

Annual PM2.5 concentrations were taken from the China High Air Pollutants (CHAP) dataset from 2000 to 2018. Two main indicators of PM2.5 were calculated for each participant: the average of annual mean PM2.5 concentrations from the year of the baseline date to the endpoint date and the previous 0- to 10-year average PM2.5 annual mean concentration for the year of the baseline date.

Incident CKD was defined as participants with an estimated glomerular filtration rate below 60 mL/min/1.73 m2 or self-reported physician diagnosed CKD. Covariates included age, sex, residence, education, body mass index, smoking and drinking status, blood pressure, fasting blood glucose, cholesterol, diabetes, hypertension, and history of cardiovascular disease (CVD).

The median (IQR) age of the participants was 38 (30-48) years, and 58% were male. The median long-term concentration exposure to PM2.5 was 70.27 (61.21-74.88) mcg/m3 for all participants in the follow-up period.

The follow-up was a median 3.79 (2.03-5.48) years; 3.02% of participants developed incident CKD in this period, with an incidence rate of 732.45 per 100,000 people. The HR for incident risk of the previous 1-year PM2.5 and cumulative average PM2.5 in the highest quartile of exposure were 1.85 (95% CI, 1.57-2.15) and 2.55 (95% CI, 2.16-3.00), respectively.

The HRs of CKD were 1.28 (95% CI, 1.21-1.36) and 1.70 (95% CI, 1.58-1.85). An association was found between the previous 1-year average PM2.5 and CKD (adjusted HR [aHR], 1.28; 95% CI, 1.21-1.36); cumulative average PM2.5 had the stronger association (aHR, 1.71; 95% CI, 1.58-1.85).

Risk of incident CKD was higher in older adults (65 years and older), patients with diabetes and CVD, patients in areas of high humidity, and patients living in environments with lower temperatures when PM2.5 was more than 74.88 mcg/m3. Overall additive interaction was only found for humidity.

In sensitivity analyses, long-term exposure to PM2.5 had the greatest risk whereas that for the 1-year average PM2.5 for CKD became insignificant after adjusting for common air pollutants.

The study has some limitations. It did not account for socioeconomic status that may be associated with development of CKD, data on population density were not available for this study, and the researchers did not have data on indoor air pollution exposure, fixed addresses for assessing PM2.5 exposure, and participants’ activity levels.

The researchers concluded that there was a positive association of long-term ambient PM2.5 exposure with risk of incident CKD in areas of high concentration.

“These findings support the conclusion that long-term exposure to PM2.5 poses a significant health risk to the general population, and additional measures and strategies are therefore needed to reduce the burden of disease caused by PM2.5 air pollution,” the authors wrote.


Duan JW, Li YL, Li SX, et al. Association of long-term ambient fine particulate matter (PM2.5) and incident CKD: a prospective cohort study in China. Am J Kidney Dis. Published online April 22, 2022. doi:10.1053/j.ajkd.2022.03.009

Related Videos
Kirsten Johansen, MD.
Jennifer Green, MD.
Related Content
© 2024 MJH Life Sciences
All rights reserved.